

Phone: (215) 489-4900 Email: info@hepb.org

Hepatitis B Foundation, B Informed Newsletter, No. 46, Summer 2006

Comparison of Costs of HBV Antiviral Therapy

(Based on average 2005 wholesale prices in the U.S.)

Drug Name	Monthly Cost	Annual Cost	FDA Status
Lamivudine (100 mg)	\$204	\$2,482	Approved
Adefovir (10 mg)	\$546	\$6,647	Approved
Entecavir (0.5 mg)	\$715	\$8,694	Approved
*Peginterferon alfa-2a (180 mcg)	\$1,540	\$18,480	Approved
	•	•	
Emtricitabine (200 mg)	\$318	\$3,872	Phase III
Tenofovir (300 mg)	\$478	\$5,811	Phase III

^{*}Although peginterferon alfa-2a has the highest monthly and annual cost, it would likely be given for only one year at most, whereas the oral agents would be given continuously for many years, or perhaps a lifetime.

Source of Data: "Costs of Antiviral Therapy of Chronic Hepatitis B," an abstract by John B. Wong, M.D., Tufts New England Medical Center, Boston, MA, that was presented at the NIH Meeting: Management of Hepatitis B on April 7, 2006.

Visit the Hepatitis B Foundation's "Drug Watch" at www.hepb.org/drugwatch

Subscribe to the free **B** Informed Newsletter of the Hepatitis B Foundation.